Skip to content
  • LinkedIn

The Business of Biofabrication

  • News
  • Perspectives
  • Learn
  • Landscape

Medical Devices

  • Xeltis Secures Nearly €50M to Advance aXess Toward Market Entry as New Data Strengthen Clinical Profile
    December 10, 2025

    Xeltis Secures Nearly €50M to Advance aXess Toward Market Entry as New Data Strengthen Clinical Profile

    Ricky Solorzano
  • The Rise of the Tiger – Tiger BioSciences: Building a Fully Integrated Platform for Regenerative Medicine
    November 28, 2025

    The Rise of the Tiger – Tiger BioSciences: Building a Fully Integrated Platform for Regenerative Medicine

    Ricky Solorzano
  • Tiger Aesthetics Invests in GenesisTissue to Advance Regenerative Breast Reconstruction
    November 17, 2025

    Tiger Aesthetics Invests in GenesisTissue to Advance Regenerative Breast Reconstruction

    Ricky Solorzano
  • Lattice Medical Raises €43M to Transform Post-Cancer Reconstruction and Scale 3D Bioprinting in France
    November 11, 2025

    Lattice Medical Raises €43M to Transform Post-Cancer Reconstruction and Scale 3D Bioprinting in France

    Ricky Solorzano
  • Why Vertex Is Staying the Course on VX-880 (Zimislecel) — Even as Novo Nordisk Pulls Back
    October 14, 2025

    Why Vertex Is Staying the Course on VX-880 (Zimislecel) — Even as Novo Nordisk Pulls Back

    Ricky Solorzano
  • Mytos Launches Automated CDMO to Scale Regenerative Cell Therapies
    October 13, 2025

    Mytos Launches Automated CDMO to Scale Regenerative Cell Therapies

    Ricky Solorzano
  • Vensana Capital Unveils Vensana Innovation, Welcomes Dr. Thomas Tu as Venture Partner
    October 8, 2025

    Vensana Capital Unveils Vensana Innovation, Welcomes Dr. Thomas Tu as Venture Partner

    Ricky Solorzano
  • Tides Medical – APLICOR 3D’s  New Personalized 3D Bioprinted Skin Graft Available for Patients at Singing River Health System
    October 7, 2025

    Tides Medical – APLICOR 3D’s New Personalized 3D Bioprinted Skin Graft Available for Patients at Singing River Health System

    Ricky Solorzano
  • CUTISS Secures CHF 56 Million Series C to Advance Phase 3 Skin-Tissue Therapy
    September 29, 2025

    CUTISS Secures CHF 56 Million Series C to Advance Phase 3 Skin-Tissue Therapy

    Ricky Solorzano
  • Humacyte Reports Positive Data on Bioengineered Vessels for Vascular Repair and Coronary Bypass
    September 22, 2025

    Humacyte Reports Positive Data on Bioengineered Vessels for Vascular Repair and Coronary Bypass

    Ricky Solorzano
Previous Page
1 2 3 4 … 6
Next Page

Archives

To make sense of, stay update on, and learn about
the business of biofabrication

Subscribe

2024 All Rights Reserved

  • Subscribe Subscribed
    The Business of Biofabrication

    Have a WordPress.com account? Log in now.

  • The Business of Biofabrication
    View site in Reader
    Manage subscriptionsSign upLog in
    Report this content
    Collapse this bar